Head-to-head evidence
Clozapine vs Fazaclo
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Fazaclo
Marketed by Jazz Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Fazaclo's landscape